2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 954

The Relationship Between Osteoarthritis and Cardiovascular Disease: Results from a Population-Based Cohort
Abstract Number: 955

Cancer Risk in 5,108 Patients with Juvenile Idiopathic Arthritis (JIA)
Abstract Number: 956

The Addition of One or More Biologics to Methotrexate in Children with Juvenile Idiopathic Arthritis Increases the Incidence of Infections and Other Adverse Events
Abstract Number: 957

Double Blind Placebo Controlled Randomized Trial of Probiotics in Enthesitis-Related-Arthritis Category of JIA: Effect on Clinical and Immunological Parameters
Abstract Number: 958

The Time Spent in Inactive Disease before MTX Withdrawal Is Relevant with Regard to the Recurrence of Active Disease in Juvenile Idiopathic Arthritis (JIA) Patients
Abstract Number: 959

Results from the Childhood Arthritis and Rheumatology Research Alliance Systemic JIA Consensus Treatment Plans Pilot Study
Abstract Number: 960

Efficacy of Canakinumab in Systemic Juvenile Idiopathic Arthritis Patients Previously Exposed to Biologics
Abstract Number: 961

Altered Th Cell Plasticity Favors Th17 Cells in Rheumatoid Arthritis
Abstract Number: 962

Profiling at the Single-Cell Level Reveals Evidence for Antigen-Driven Oligoclonal Expansion of Citrullinated Vimentin-Specific CD4+ T Cells in Peripheral Blood of Rheumatoid Arthritis (RA) Patients
Abstract Number: 963

Ectopic Lymphoid Tissue in the Lung Is Associated with Serum Rheumatoid Arthritis-Related Autoantibodies Even in Absence of Clinically Apparent Rheumatoid Arthritis
Abstract Number: 964

Neutrophil Extracellular Traps Are Not Only Targets for ACPA-Positive IgG from Rheumatoid Arthritis Patients but Also Directly Trigger Pro- and Anti-Inflammatory Effects Partly Mediated By the C1q Complement Protein
Abstract Number: 965

Crystal Structure of Porphyromonas Gingivalis peptidylarginine Deiminase: Implications for Autoimmunity in Rheumatoid Arthritis
Abstract Number: 966

In Rheumatoid Arthritis, Smoking Is Not Associated with Anti-Citrullinated Protein Antibodies per Se, but with the Concurrent Presence of Rheumatoid Factor, Anti-Citrullinated Protein Antibodies and Anti-Carbamylated Protein Antibodies
Abstract Number: 967

Safety, Tolerability, and Pharmacodynamics of ABT-122, a Dual TNF- and IL-17-Targeted Dual Variable Domain (DVD)-IgTM in Subjects with Rheumatoid Arthritis
Abstract Number: 968

Certolizumab Pegol in Combination with Methotrexate in DMARD-Naïve Patients with Active, Severe, Progressive Rheumatoid Arthritis: Results from a Randomized, Double-Blind, Controlled Phase 3 Study

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].